Advertisement

European Journal of Applied Physiology

, Volume 118, Issue 4, pp 729–736 | Cite as

Opinion paper: scientific, philosophical and legal consideration of doping in sports

  • Massimo Negro
  • Natale Marzullo
  • Francesca Caso
  • Luca Calanni
  • Giuseppe D’Antona
Invited Review

Abstract

The term doping is generally used to indicate practices based on the use of performance-enhancing drugs (PEDs) or the abuse of medical therapies. Mostly analysed by doctors and officials, doping nevertheless also requires a philosophical consideration to avoid being simplistically portrayed as an isolated practice. To do this, we need to pay attention to the contradictions and paradoxes in the modern approach to doping in sport. In this context, doping is not only relevant to the health of an individual involved in the violation of World Anti-Doping Agency (WADA) criteria, but it actually represents a double-edged phenomenon containing ethical and legal points of view. Several philosophical items affect the ethics of doping. While, indeed, through a deontological vision it is easy to morally condemn an athlete who takes the decision to turn to doping, the same condemnation becomes difficult when the practice of doping is compared with the strong social demand of winners in every field of life. This point must be considered to prevent doping from becoming accepted as a daily practice to excel at all costs and regarded not only as normal but as a necessity for those participating in sport at both an amateur and professional level. Furthermore, a complete discussion on doping has to consider not only the philosophy of performance-enhancing drug abuse, but also the widespread practice of an inappropriate and excessive intake of certain dietary supplements with the unique and obsessive purpose (similar to doping) of increasing physical or mental performance. Based on the above, the aim of this paper is to provide a critical opinion of the doping problem and its related practices and analyze possible solutions considering issues that go beyond the impact of doping on health and reflect on whether it is right or not that an athlete does all he can to improve his performance.

Graphical Abstract

Keywords

Sports doping Enhancement Ethics Philosophical ethics 

Abbreviations

PEDs

Performance-enhancing drugs

GMP

Good manufacturing practice

IOC

International Olympic Committee

WADA

World Anti-Doping Agency

Notes

Author contributions

All authors contributed to the writing of the manuscript; NM and GD conceived the original idea of the manuscript.

References

  1. Budnitz DS, Pollock DA, Weidenbach KN et al (2006) National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296:1858–1866CrossRefPubMedGoogle Scholar
  2. Casini L (2012) The making of a lex sportiva by the Court of Arbitration of sports. In: Siekmann R, Soek J (eds) Lex Sportiva: what is sport law? ASSER International Sports Law Series. C. Asser Press, T. M., pp 149–171CrossRefGoogle Scholar
  3. Cohen PA (2012) Assessing supplement safety—the FDA’s controversial proposal. N Engl J Med 366:389–391CrossRefPubMedGoogle Scholar
  4. Colucci M (2010) Sports law in Italy. Wolters Kluwer—Law & Business, AustinGoogle Scholar
  5. Dambrova M, Liepinsh E (2016) Response to comment by Sergei V. Jargin: “Meldonium (Mildronate): primum nоn nocere”. Pharmacol Res 114:295–296CrossRefPubMedGoogle Scholar
  6. Derrida J (1995) The rhetoric of drugs. In: Weber E (ed) Points… Interviews, 1974–1994. Stanford University Press, Stanford CA, pp 228–254Google Scholar
  7. Duret P, Wolff M (1994) The semiotics of sports heroism. Int Rev Soc Sport 29:135–145CrossRefGoogle Scholar
  8. Foucault M (1977) Discipline and punish: the Birth of the prison (translated from the French by Alan Sheridan). Vintage Books a division of random house, New YorkGoogle Scholar
  9. Geller AI, Shehab N, Weidle NJ et al (2015) Emergency department visits for adverse events related to dietary supplements. N Engl J Med 373:1531–1540CrossRefPubMedGoogle Scholar
  10. Greenblatt HK, Greenblatt DJ (2016) Meldonium (Mildronate): a performance-enhancing drug? Clin Pharmacol Drug Dev 5:167–169CrossRefPubMedGoogle Scholar
  11. Jargin SV (2016) Meldonium (Mildronate): primum nоn nocere. Pharmacol Res 114:294CrossRefPubMedGoogle Scholar
  12. Kayser B, Mauron A, Miah A (2007) The current anti-doping policy: a critical appraisal. BMC Med Ethics 8:2CrossRefPubMedPubMedCentralGoogle Scholar
  13. La Gerche A, Brosnan MJ (2017) cardiovascular effects of performance-enhancing drugs. Circulation 135:89–99CrossRefPubMedGoogle Scholar
  14. Liepinsh E, Konrade I, Skapare E et al (2011) Mildronate treatment alters γ-butyrobetaine and l-carnitine concentrations in healthy volunteers. J Pharm Pharmacol 63:1195–1201CrossRefPubMedGoogle Scholar
  15. Miah A (2004) Genetically modified athletes. Biomedical ethics, gene doping and sport. Routledge (Taylor & Francis Group), London and New YorkGoogle Scholar
  16. Mottram DR, Chester N (2015) Prohibited supplements. In: Mottram DR, Chester N (eds) Drugs in Sport, 6th edn. Routledge (Taylor & Francis Group), London and New York, p 335Google Scholar
  17. Navarro V, Khan I, Björnsson E et al (2017) liver injury from herbal and dietary supplements. Hepatology 65(1):363–373CrossRefPubMedGoogle Scholar
  18. Nutrition Business Journal Global Supplement and Nutrition Industry Report (2014) Nutr Bus J. http://newhope360.com/site-files/newhope360.com/files/uploads/2014/Global_Report%20summary.pdf. Accessed 23 Sep 2017
  19. Pope HG Jr, Wood RI, Rogol A et al (2014) Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev 35:341–375CrossRefPubMedGoogle Scholar
  20. Savulescu J (2006) Justice, fairness, and enhancement. Ann N Y Acad Sci 1093:321 – 38CrossRefPubMedGoogle Scholar
  21. Schobersberger W, Dünnwald T, Gmeiner G et al (2017) Story behind meldonium-from pharmacology to performance enhancement: a narrative review. Br J Sports Med 51:22–25CrossRefPubMedGoogle Scholar
  22. Smith AC, Stewart B (2015) Why the war on drugs in sport will never be won. Harm Reduct J 12:53CrossRefPubMedPubMedCentralGoogle Scholar
  23. World Anti-Doping Agency (WADA) Official web site. http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-The-Code/WADA_Anti-Doping_CODE_2009_EN.pdf. Accessed 10 Oct 2017
  24. World Anti-Doping Agency (WADA) Official web site. https://www.wada-ama.org/en/media/news/2017-12/wada-statement-regarding-the-iocs-decision-concerning-russia. Accessed 5 Jan 2018

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.CRIAMS-Sport Medicine CentreUniversity of PaviaVogheraItaly
  2. 2.Department of Public Health, Experimental and Forensic MedicineUniversity of PaviaPaviaItaly

Personalised recommendations